nobody's mad . folks put in hours of research and put their money where their mouth is. Let's not belittle them . Make your money and walk away . don't gloat or you can lose them in a jiffy. what goes around comes around.
those who are in for a quick buck should just sell and move on. this stock is not for you. just sell at market and move on to the next horse. Just leave cycc alone to the long term shareholders, the market makers and the short sellers. and please don't come back in to CYCC.
AMBI was a 200-300mln market cap company that's 3 years behind cyclacel in terms of AML product development. you can be sure biotech investors ain't very sharp with their read of what's fair value for a biotech company.
shorties will probably cover should the stock start hitting above 300mln market cap. Most short term shorties shorted when cycc was around 80mln market cap hoping it will be cut in half to 40mln . which is approximately their cash levels.
for a lowly floated stock prices are meaningless. .. It's better we use market cap . Say something like 300-400mln market cap etc.
shorts are taking their own calculated gamble. The retails are putting money which they are prepared to write off into cycc . On top of that CYCC is non marginable. so not sure what long squeeze are they looking for . If this stock were like ARIA 800mln-3bln market cap. its worth a try.
PCYC at its low was a 35mln drug company which many thought was just another scam. Its grown to a 9bln market cap company in 4 years. We are just a small David with dim prospects for now. But don't write us off. ...or you might just miss a royal flush
The key development that will propel CYCC into the big 5-20bln market cap league is not cyc116 . Its Seliciclib (CYC202). Sapa will just add 500-mln - 1.5b to the market cap. But the drug with the potential is Seliciclib (CYC202). I can only hope they secure the funds from a big boy and accelerate the development process there.
there will come a day where it gaps up at 400-800mln market cap or opens down at 60 mln market cap. the dollar per se ticker prints are meaningless.
let's just bear in mind that longs haven't won anything yet. its just minor fluctuations within a $60-90mln market cap for now. nothing to rejoice. if it hits north of 800mln market cap then that's a minor achievement. $8bln market cap then its a mini pharmacyclics windfall. else there's nothing to shout about for now.
Sentiment: Strong Buy
say you are the big boutique fund. flashy trader who managed to short the entire 2 mln shares out there stated as short interest on nasdaq at $4.3 average the last month . Is it worth the risk to take for a $60mln market cap company? $1 bln gold mining stock or a $178b BHP might just let you breathe easier . and you don't have to check back the stock price for this guy or yahoo boards every 5 mins
feels like november's short interest will be up again . probably around 2 mln shares. line in the sand of shorties should be $12. sellers are just market makers or shorties. long bag holders are all in the $20-50 range and watching apple stock now.
just a few retail buying now. nothing to cheer. . line in the sand is $12 . that's when the shorts start to buy back. $1 downside $50 upside . i'm sure the shorties are great with their math.
you don't have to repeat this every single day. poor b. bashing a 60m market cap stock predicting it will be cut in half. aint' got nothing better to do .
ARIAD's inclusig is a direct competitor to sapacitabine in AML . ARIA is 1 step behind CYCC and 3bln richer in market cap yesterday before these blood clotting issues . fools
ariad's about a $3bln market cap company just yesterday. CYCC's sapacitabine AML proposition is working fine thank you.